Subtype
Throat Carcinoma
CI-CAN-00006917Explore in graph →
369 active trials1 approved drugs2 evidence items
- NCIt
- C35506
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006917Explore in graph →
Clinical trials
1,035 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (87)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02381535 | Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | completed | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT04871490 | Improving Detection and Early Action for HPV-positive Oropharynx Cancer(IDEA-HPV) | completed | N/A | 40 | Brigham and Women's HospitalOTHER | 1 | Feb 5, 2025 |
| clinicaltrials |
| NCT05834712 | Patients With Stage III-IVa Nasopharyngeal Carcinoma With or Without a Mobile Medical Platform Full-course Nutritional Intervention | completed | N/A | 224 | Sun Yat-sen UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05292027 | Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | completed | N/A | 84 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04996758 | Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) | completed | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06676293 | Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma | completed | N/A | 8 | Chang Gung Memorial HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT04895345 | A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02258659 | Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer(OPTIMA) | completed | Phase 2 | 62 | University of ChicagoOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT03028766 | WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer(WISTERIA) | completed | Phase 1 | 9 | University of BirminghamOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04220307 | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 34 | AkesoINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06314711 | Ex Vivo 3D-ultrasound for Oropharyngeal Cancer | completed | N/A | 15 | Rigshospitalet, DenmarkOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT04417985 | Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma | completed | N/A | 112 | Chang Gung Memorial HospitalOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT01847326 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer | completed | Phase 1 | 48 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05330169 | Hearing Impairment of Nasopharyngeal Carcinoma | completed | — | 200 | Guangxi Medical UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT01064479 | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03752398 | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)(DUET-3) | completed | Phase 1 | 198 | Xencor, Inc.INDUSTRY | 1 | Jul 5, 2024 | clinicaltrials |
| NCT04541355 | Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin | completed | Phase 2 | 16 | Hyunseok Kang, MDOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT04995185 | 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study | completed | N/A | 9 | National Cancer Centre, SingaporeOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT04396886 | Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC | completed | Phase 2 | 38 | The University of Hong KongOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT02072148 | The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) | completed | N/A | 112 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03025958 | Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06367049 | Methylation-specific PCR Test for Early Screening and Early Diagnosis of Nasopharyngeal Carcinoma | completed | — | 470 | Sun Yat-sen UniversityOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03558191 | SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy. | completed | Phase 2 | 156 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03788499 | Using Massage of Maxillofacial and Oral Cavity to Prevent Radioactive Oral Mucositis | completed | N/A | 160 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT03791944 | 3DV+TPS Applied to Radiotherapy for Nasopharyngeal Carcinoma | completed | N/A | 100 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06244394 | Retrospective Study on the Prediction of Radiation-induced Brain Injury in Patients With Nasopharyngeal Carcinoma | completed | — | 230 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03906058 | Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT05217147 | An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma | completed | — | 80 | Hacettepe UniversityOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT03598218 | Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma | completed | N/A | 30 | Wei JiangOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04929080 | The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC | completed | Phase 1 / Phase 2 | 149 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT00834093 | A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma | completed | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02578641 | A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients(VANCE) | completed | Phase 3 | 330 | Tessa TherapeuticsINDUSTRY | 5 | Jun 28, 2023 | clinicaltrials |
| NCT01935921 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01711541 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2023 | clinicaltrials |
| NCT03429868 | PET and MRI in Prognosis Prediction of NPC | completed | N/A | 180 | Chang Gung Memorial HospitalOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT02940925 | TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma | completed | Phase 3 | 241 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04945421 | IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC | completed | Phase 1 | 30 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Feb 23, 2023 | clinicaltrials |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Wei JiangOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT03032250 | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer | completed | N/A | 35 | Wake Forest University Health SciencesOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01088802 | Treatment De-Intensification for Squamous Cell Carcinoma of the Oropharynx | completed | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT04636632 | Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma | completed | Phase 1 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Feb 11, 2025source: clinicaltrials